Mentor Worldwide, a company specializing in breast aesthetics, and part of Johnson & Johnson MedTech, today announced the FDA approved MENTOR MemoryGel Enhance Breast Implants for primary and revision reconstruction breast surgery in post-mastectomy women. This first-of-its-kind silicone gel-filled implant line features an expanded range of base widths, projections, and volumes in an entirely new range of sizes extending from 930 cc to 1445 cc, the largest on the market. Mentor plans to commercially launch MemoryGel Enhance Breast Implants in the U.S. beginning in mid-2025.
With the launch of MemoryGel Enhance Breast Implants, breast reconstruction patients in need of larger implants are afforded the same clinical benefits as those patients for whom proportionately sized implants are already available. This new implant line will enable surgeons to deliver desired results for women who were previously underserved, having limited options to regain their original breast size or achieve projection and symmetry with the unaffected breast.
“The size of implants currently on the market is not reflective of the diverse body types of women, especially women with larger cup sizes who undergo reconstructive surgery following a breast cancer diagnosis,” says Alanna Rebecca, M.D., plastic and reconstructive surgeon at the Mayo Clinic in Phoenix, Arizona, and co-author of the anticipated ATHENA study publication. “A woman’s body type should never limit her options in reconstruction, which is why this latest approval is an exciting step for the breast cancer community as we pave the way for inclusivity along the full continuum of breast cancer care.”
This approval is supported by 3-year findings from the prospective, multicenter, ongoing 10-year ATHENA study, which demonstrated the safety and effectiveness of MemoryGel Enhance larger-volume silicone breast implants after three years, in women who underwent post mastectomy and implant-based breast reconstruction.
Mentor’s FDA approval of MemoryGel Enhance Breast Implants marks a significant advancement in breast reconstruction, exemplifying the company’s commitment to stand behind all women with a more comprehensive and inclusive portfolio enabling surgeons to offer more personalized options for their patients and expand the population they serve by addressing a broader and more diverse range of women’s needs.
